The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Doxorubicin induced heart failure: Phenotype and molecular mechanisms
Open accessAbstract
Long term survival of childhood cancers is now more than 70%. Anthracyclines, including doxorubicin, are some of the most efficacious anticancer drugs available. However, its use as a chemotherapeutic agent is severely hindered by its dose-limiting toxicities. Most notably observed is cardiotoxicity, but other organ systems are also degraded by doxorubicin use. Despite the years of its use and the amount of information written about this drug, an understanding of its cellular mechanisms is not fully appreciated. The mechanisms by which doxorubicin induces cytotoxicity in target cancer cells have given insight about how the drug damages cardiomyocytes. The major mechanisms of doxorubicin actions are thought to be as an oxidant generator and as an inhibitor of topoisomerase 2. However, other signaling pathways are also invoked with significant consequences for the cardiomyocyte. Further the interaction between oxidant generation and topoisomerase function has only recently been appreciated and the consequences of this interaction are still not fully understood. The unfortunate consequences of doxorubicin within cardiomyocytes have promoted the search for new drugs and methods that can prevent or reverse the damage caused to the heart after treatment in cancer patients. Alternative protocols have lessened the impact on newly diagnosed cancer patients. However the years of doxorubicin use have generated a need for monitoring the onset of cardiotoxicity as well as understanding its potential long-term consequences. Although a fairly clear understanding of the short-term pathologic mechanisms of doxorubicin actions has been achieved, the long-term mechanisms of doxorubicin induced heart failure remain to be carefully delineated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Doxorubicin pathways: pharmacodynamics and adverse effects
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,648
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.006 · Cited by 1,414
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Clinical Ascertainment of Health Outcomes Among Adults Treated for Childhood Cancer
Hudson, M. M., Ness, K. K., Gurney, J. G., Mulrooney, D. A., Chemaitilly, W., Krull, K. R., Green, D. M., Armstrong, G. T., Nottage, K. A., Jones, K. E., et al. (2013) · JAMA · doi:10.1001/jama.2013.6296 · Cited by 1,248
Leitman, M., Lysyansky, P., Sidenko, S., Shir, V., Peleg, E., Binenbaum, M., Kaluski, E., Krakover, R., & Vered, Z. (2004) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2004.06.019 · Cited by 1,187
Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010) · Cardiology · doi:10.1159/000265166 · Cited by 1,065
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Medical Assessment of Adverse Health Outcomes in Long-term Survivors of Childhood Cancer
Geenen, M. M., Cardous-Ubbink, M. C., Kremer, L. C. M., van den Bos, C., van der Pal, H. J. H., Heinen, R. C., Jaspers, M. W. M., Koning, C. C. E., Oldenburger, F., Langeveld, N. E., et al. (2007) · JAMA · doi:10.1001/jama.297.24.2705 · Cited by 860
Šimůnek, T., Štěrba, M., Popelová, O., Adamcová, M., Hrdina, R., & Geršl, V. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70018-0 · Cited by 769
Anthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00008 · Cited by 749
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., Oguzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 713
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Davies, K. J., & Doroshow, J. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35746-0 · Cited by 631
Aconitase as iron–sulfur protein, enzyme, and iron-regulatory protein
Beinert, H., Kennedy, M. C., & Stout, C. D. (1996) · Chemical Reviews · doi:10.1021/cr950040z · Cited by 606
Anthracycline cardiomyopathy monitored by morphologic changes.
Billingham, M. E., Mason, J. W., Bristow, M. R., & Daniels, J. R. (1978) · PubMed · Cited by 586
Doroshow, J. H., & Davies, K. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35747-2 · Cited by 540
Childs, A. C., Phaneuf, S., Dirks, A. J., Phillips, T., & Leeuwenburgh, C. (2002) · PubMed · Cited by 525
Tebbi, C. K., London, W. B., Friedman, D., Villaluna, D., De Alarcon, P. A., Constine, L. S., Mendenhall, N. P., Sposto, R., Chauvenet, A., & Schwartz, C. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.3879 · Cited by 493
Fallah-Rad, N., Walker, J. R., Wassef, A., Lytwyn, M., Bohonis, S., Fang, T., Tian, G., Kirkpatrick, I. D. C., Singal, P. K., Krahn, M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.063 · Cited by 484
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing
Deweese, J. E., & Osheroff, N. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn937 · Cited by 462
Cardiotoxicity of Cancer Therapy
Floyd, J. D., Nguyen, D. T., Lobins, R. L., Bashir, Q., Doll, D. C., & Perry, M. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.789 · Cited by 372
Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity
Lotrionte, M., Biondi-Zoccai, G., Abbate, A., Lanzetta, G., D'Ascenzo, F., Malavasi, V., Peruzzi, M., Frati, G., & Palazzoni, G. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.026 · Cited by 371
Fisher, P. W., Salloum, F., Das, A., Hyder, H., & Kukreja, R. C. (2005) · Circulation · doi:10.1161/01.cir.0000160359.49478.c2 · Cited by 355
Armstrong, G. T., Plana, J. C., Zhang, N., Srivastava, D., Green, D. M., Ness, K. K., Daniel Donovan, F., Metzger, M. L., Arevalo, A., Durand, J.-B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3584 · Cited by 321
Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin.
Zhou, S., Starkov, A. A., Froberg, M. K., Leino, R. L., & Wallace, K. B. (2001) · PubMed · Cited by 314
Rafiyath, S. M., Rasul, M., Lee, B., Wei, G., Lamba, G., & Liu, D. (2012) · Experimental Hematology & Oncology · doi:10.1186/2162-3619-1-10 · Cited by 302
Swain, S. M., Whaley, F. S., Gerber, M. C., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1333 · Cited by 269
Kremer, L. C. M., van Dalen, E. C., Offringa, M., & Voûte, P. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf118 · Cited by 249
Ho, E., Brown, A., Barrett, P., Morgan, R. B., King, G., Kennedy, M. J., & Murphy, R. T. (2010) · Heart · doi:10.1136/hrt.2009.173997 · Cited by 242
Strumberg, D., Brügge, S., Korn, M. W., Koeppen, S., Ranft, J., Scheiber, G., Reiners, C., Möckel, C., Seeber, S., & Scheulen, M. E. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf058 · Cited by 232
Cannabinoids Acting on CB1 Receptors Decrease Contractile Performance in Human Atrial Muscle
Bonz, A., Laser, M., Küllmer, S., Kniesch, S., Babin-Ebell, J., Popp, V., Ertl, G., & Wagner, J. A. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200304000-00020 · Cited by 229
Kalivendi, S. V., Kotamraju, S., Zhao, H., Joseph, J., & Kalyanaraman, B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106829200 · Cited by 225
Activation of topoisomerase II-mediated excision of chromosomal DNA loops during oxidative stress
Li, T.-K., Chen, A. Y., Yu, C., Mao, Y., Wang, H., & Liu, L. F. (1999) · Genes & Development · doi:10.1101/gad.13.12.1553 · Cited by 213
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
Das, A., Durrant, D., Salloum, F. N., Xi, L., & Kukreja, R. C. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.10.003 · Cited by 212
Spinale, F. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00431-9 · Cited by 211
Mukhopadhyay, P., Bátkai, S., Rajesh, M., Czifra, N., Harvey-White, J., Haskó, G., Zsengeller, Z., Gerard, N. P., Liaudet, L., Kunos, G., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.03.057 · Cited by 207
Cardiac Failure and Dysrhythmias 6–19 Years After Anthracycline Therapy: A Series of 15 Patients
Steinherz, L. J., Steinherz, P. G., & Tan, C. (1995) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950240604 · Cited by 192
Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms
Deng, S., Yan, T., Jendrny, C., Nemecek, A., Vincetic, M., Gödtel-Armbrust, U., & Wojnowski, L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-842 · Cited by 176
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes
Lipshultz, S. E., Miller, T. L., Lipsitz, S. R., Neuberg, D. S., Dahlberg, S. E., Colan, S. D., Silverman, L. B., Henkel, J. M., Franco, V. I., Cushman, L. L., et al. (2012) · Pediatrics · doi:10.1542/peds.2012-0727 · Cited by 175
Acute arrhythmogenicity of doxorubicin administration
Steinberg, J. S., Cohen, A. J., Wasserman, A. G., Cohen, P., & Ross, A. M. (1987) · Cancer · doi:10.1002/1097-0142(19870915)60:6<1213::aid-cncr2820600609>3.0.co;2-v · Cited by 171
Apoptosis in Adriamycin Cardiomyopathy and Its Modulation by Probucol
Kumar, D., Kirshenbaum, L. A., Li, T., Danelisen, I., & Singal, P. K. (2001) · Antioxidants & Redox Signaling · doi:10.1089/152308601750100641 · Cited by 159
Review of Tests for Monitoring Doxorubicin-lnduced Cardiomyopathy
Ganz, W. I., Sridhar, K. S., Ganz, S. S., Gonzalez, R. R., Chakko, S. C., & Serafini, A. N. (2009) · Oncology · doi:10.1159/000227621 · Cited by 151
Lebrecht, D., Geist, A., Ketelsen, U., Haberstroh, J., Setzer, B., & Walker, U. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707294 · Cited by 136
Lynn, R. M., Bjornsti, M., Caron, P. R., & Wang, J. C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3559 · Cited by 135
Combination therapy with probucol prevents adriamycin-induced cardiomyopathy
Singal, P. K. (1995) · Journal of Molecular and Cellular Cardiology · doi:10.1016/0022-2828(95)90074-8 · Cited by 131
Potentiation of Doxorubicin Cardiotoxicity by Iron Loading in a Rodent Model
Panjrath, G. S., Patel, V., Valdiviezo, C., Narula, N., Narula, J., & Jain, D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.060 · Cited by 126
Dual localization of human DNA topoisomerase IIIα to mitochondria and nucleus
Wang, Y., Lyu, Y. L., & Wang, J. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192449499 · Cited by 119
Early Detection of Doxorubicin Cardiomyopathy Using Two-Dimensional Strain Echocardiography
Migrino, R. Q., Aggarwal, D., Konorev, E. A., Brahmbhatt, T., Bright, M., & Kalyanaraman, B. (2007) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2007.07.018 · Cited by 118
Barry, E. V., Vrooman, L. M., Dahlberg, S. E., Neuberg, D. S., Asselin, B. L., Athale, U. H., Clavell, L. A., Larsen, E. C., Moghrabi, A., Samson, Y., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2481 · Cited by 118
Cardiotoxicity and Oncological Treatments
Schlitt, A., Jordan, K., Vordermark, D., Schwamborn, J., Langer, T., & Thomssen, C. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0161 · Cited by 118
Targeted Delivery of Doxorubicin by Folic Acid-Decorated Dual Functional Nanocarrier
Lu, J., Zhao, W., Huang, Y., Liu, H., Marquez, R. T., Gibbs, R. B., Jiang, L., Venkataramanan, R., Xu, L., Li, S., et al. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500389v · Cited by 118
Pathophysiology and diagnosis of cancer drug induced cardiomyopathy
Zuppinger, C., Timolati, F., & Suter, T. M. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0016-2 · Cited by 113
The Endothelin Receptor Blocker Bosentan Inhibits Doxorubicin-Induced Cardiomyopathy
Bien, S., Riad, A., Ritter, C. A., Gratz, M., Olshausen, F., Westermann, D., Grube, M., Krieg, T., Ciecholewski, S., Felix, S. B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1344 · Cited by 111
El‐Shitany, N. A., Tolba, O., El-Shanshory, M. R., & Elhawary, E. E. (2012) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2012.06.416 · Cited by 109
Viner, R., Hsia, Y., Tomsic, T., & Wong, I. C. K. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00651.x · Cited by 107
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
Javle, M. M., & Curtin, N. J. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011417039 · Cited by 104
Perturbation of microRNAs in Rat Heart during Chronic Doxorubicin Treatment
Vacchi‐Suzzi, C., Bauer, Y., Berridge, B. R., Bongiovanni, S., Gerrish, K., Hamadeh, H. K., Letzkus, M., Lyon, J. J., Moggs, J. G., Paules, R. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040395 · Cited by 99
Reddy, L. H., & Murthy, R. S. R. (2004) · Biomedical Papers · doi:10.5507/bp.2004.029 · Cited by 93
Preferential binding of human topoisomerase I to superhelical DNA.
Madden, K. R., Stewart, L. J., & Champoux, J. J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00224.x · Cited by 92
Cardiotoxic Consequences of Anthracycline-Containing Therapy in Patients With Breast Cancer
Jensen, B. V. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.022 · Cited by 92
Plasma miR‐208 as a useful biomarker for drug‐induced cardiotoxicity in rats
Nishimura, Y., Kondo, C., Morikawa, Y., Tonomura, Y., Torii, M., Yamate, J., & Uehara, T. (2014) · Journal of Applied Toxicology · doi:10.1002/jat.3044 · Cited by 91
Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials
Bast, A., Haenen, G. R. M. M., Bruynzeel, A. M. E., & van der Vijgh, W. J. F. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0018-0 · Cited by 86
Ganz, P. A., Hussey, M. A., Moinpour, C. M., Unger, J. M., Hutchins, L. F., Dakhil, S. R., Giguere, J. K., Goodwin, J. W., Martino, S., & Albain, K. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8877 · Cited by 85
Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity
Bai, P., Mabley, J. G., Liaudet, L., Virág, L., Szabó, C., & Pacher, P. (2004) · Oncology Reports · doi:10.3892/or.11.2.505 · Cited by 74
A truncated form of DNA topoisomerase IIβ associates with the mtDNA genome in mammalian mitochondria
Low, R. L., Orton, S., & Friedman, D. B. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03814.x · Cited by 69
Ivanová, M., Dovinová, I., Okruhlicová, Ľ., Tribulová, N., Šimončíková, P., Barteková, M., Vlkovičová, J., & Barančík, M. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.194 · Cited by 63
Spontaneous DNA Damage Stimulates Topoisomerase II-mediated DNA Cleavage
Kingma, P. S., & Osheroff, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.11.7488 · Cited by 62
van Boxtel, W., Bulten, B. F., Mavinkurve‐Groothuis, A. M. C., Bellersen, L., Mandigers, C. M. P. W., Joosten, L. A. B., Kapusta, L., de Geus‐Oei, L., & van Laarhoven, H. W. M. (2015) · Biomarkers · doi:10.3109/1354750x.2015.1040839 · Cited by 61
Cytofluorescence detection of adriamycin-mitochondria interactions in isolated, perfused rat heart
Nicolay, K., Fok, J. J., Voorhout, W. F., Post, J. A., & KRUIJFF, B. D. (1986) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(86)90119-9 · Cited by 61
Makkouk, A., Joshi, V. B., Wongrakpanich, A., Lemke-Miltner, C. D., Gross, B., Salem, A. K., & Weiner, G. J. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9676-6 · Cited by 59
Goetzenich, A., Hatam, N., Zernecke, A., Weber, C., Czarnotta, T., Autschbach, R., & Christiansen, S. (2009) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2009.06.025 · Cited by 48
Lenčová-Popelová, O., Jirkovský, E., Mazurová, Y., Lenčo, J., Adamcová, M., Šimůnek, T., Geršl, V., & Štěrba, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096055 · Cited by 47
Mitochondrial topoisomerases and alternative splicing of the human TOP1mt gene
Zhang, H., Meng, L., & Pommier, Y. G. (2006) · Biochimie · doi:10.1016/j.biochi.2006.11.002 · Cited by 47
Topoisomerase IIα-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin
Yan, T., Deng, S., Metzger, A., Gödtel‐Armbrust, U., Porter, A. C. G., & Wojnowski, L. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0139 · Cited by 46
Yoshida, K., Yamaguchi, T., Shinagawa, H., Taira, N., Nakayama, K. I., & Miki, Y. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.9.3414-3431.2006 · Cited by 45
Bryant, J., Picot, J., Baxter, L. C., Levitt, G., Sullivan, I. D., & Clegg, A. J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603562 · Cited by 38
Swift, L. P., Cutts, S. M., Nudelman, A., Levovich, I., Rephaeli, A., & Phillips, D. R. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0528-2 · Cited by 37
Miyagawa, K., Emoto, N., Widyantoro, B., Nakayama, K., Yagi, K., Rikitake, Y., Suzuki, T., & Hirata, K. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.141903 · Cited by 36
Casein kinase I / phosphorylates topoisomerase II at serine-1106 and modulates DNA cleavage activity
Grozav, A. G., Chikamori, K., Kozuki, T., Grabowski, D., Bukowski, R. M., Willard, B. B., Kinter, M. T., Andersen, A. H., Ganapathi, R. N., & Ganapathi, M. K. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn934 · Cited by 35
Bau, J. T., Kang, Z., Austin, C. A., & Kurz, E. U. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.088963 · Cited by 32
Cited by
Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111708 · Cited by 909
Molecular mechanism of doxorubicin-induced cardiomyopathy – An update
Renu, K., V.G., A., P.B., T. P., & Arunachalam, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.043 · Cited by 588
Wenningmann, N., Knapp, M., Ande, A., Vaidya, T. R., & Ait-Oudhia, S. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.115725 · Cited by 334
Sex Differences in Cancer: Epidemiology, Genetics and Therapy
Kim, H.-I., Lim, H., & Moon, A. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.103 · Cited by 315
Cardiac spheroids as promising in vitro models to study the human heart microenvironment
Polonchuk, L., Chabria, M., Badi, L., Hoflack, J.-C., Figtree, G., Davies, M. J., & Gentile, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-06385-8 · Cited by 223
Metadata
- Authors
- Mitry, M. A., & Edwards, J. G.
- Venue
- IJC Heart & Vasculature
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 10
- Pages
- 17-24
- ISSN
- 2352-9067 (ISSN-L)
- OpenAlex
- W2173735004
- Cited by
- 311
- References
- 81
- FWCI
- 11.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.